BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-κB binding site of the uPA promoter

被引:59
作者
Cicek, Muzaffer [2 ]
Fukuyama, Ryuichi [3 ]
Cicek, Mine S. [4 ]
Sizemore, Steven [3 ]
Welch, Danny R. [5 ,6 ]
Sizemore, Nywana [3 ]
Casey, Graham [1 ]
机构
[1] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA
[2] Mayo Clin, Endocrine Res Unit, Coll Med, Rochester, MN 55905 USA
[3] Cleveland Clin, Lerner Sch Med, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA
[4] Mayo Clin, Coll Med, Lab Med & Pathol, Rochester, MN 55905 USA
[5] Univ Alabama, Dept Pathol, Ctr Comprehens Canc, Birmingham, AL 35294 USA
[6] Univ Alabama, Natl Fdn Canc Res Ctr Metastasis Res, Birmingham, AL 35294 USA
关键词
BRMS1; NF-kappa B; HDAC1; METASTASIS SUPPRESSOR-1 BRMS1; BREAST-CANCER CELLS; CARCINOMA METASTASIS; DEACETYLASE COMPLEX; P65; SUBUNIT; TRANSCRIPTION; PATHWAYS; KINASES; FAMILY;
D O I
10.1007/s10585-009-9235-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The BRMS1 metastasis suppressor was recently shown to negatively regulate NF-kappa B signaling and down regulate NF-kappa B-dependent uPA expression. Here we confirm that BRMS1 expression correlates with reduced NF-kappa B DNA binding activity in independently derived human melanoma C8161.9 cells stably expressing BRMS1. We show that knockdown of BRMS1 expression in these cells using small interfering RNA (siRNA) leads to the reactivation of NF-kappa B DNA binding activity and re-expression of uPA. Further, we confirm that BRMS1 expression does not alter IKK beta kinase activity suggesting that BRMS1-dependent uPA regulation does not occur through inhibition of the classical upstream activators of NF-kappa B. BRMS1 has been implicated as a corepressor of HDAC1 and consistent with this, we show that BRMS1 promotes HDAC1 recruitment to the NF-kappa B binding site of the uPA promoter and is associated with reduced H3 acetylation. We also confirm that BRMS1 expression stimulates disassociation of p65 from the NF-kappa B binding site of the uPA promoter consistent with its reduced DNA binding activity. These data suggest that BRMS1 recruits HDAC1 to the NF-kappa B binding site of the uPA promoter, modulates histone acetylation of p65 on the uPA promoter, leading to reduced NF-kappa B binding activity on its consensus sequence, and reduced transactivation of uPA expression.
引用
收藏
页码:229 / 237
页数:9
相关论文
共 28 条
[11]  
Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO
[12]  
2-Z
[13]   Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy [J].
Nash, Kevin T. ;
Phadke, Pushkar A. ;
Navenot, Jean-Marc ;
Hurst, Douglas R. ;
Accavitti-Loper, Mary Ann ;
Sztul, Elizabeth ;
Vaidya, Kedar S. ;
Frost, Andra R. ;
Kappes, John C. ;
Peiper, Stephen C. ;
Welch, Danny R. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (04) :309-321
[14]   Identification of a novel BRMS1-homologue protein p40 as a component of the mSin3A/p33ING1b/HDAC1 deacetylase complex [J].
Nikolaev, AY ;
Papanikolaou, NA ;
Li, MY ;
Qin, J ;
Gu, W .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 323 (04) :1216-1222
[15]   IκB kinases phosphorylate NF-κB p65 subunit on serine 536 in the transactivation domain [J].
Sakurai, H ;
Chiba, H ;
Miyoshi, H ;
Sugita, T ;
Toriumi, W .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (43) :30353-30356
[16]   Breast cancer metastasis suppressor I (BRMSI) inhibits osteopontin transcription by abrogating NF-κB activation [J].
Samant, Rajeev S. ;
Clark, David W. ;
Fillmore, Rebecca A. ;
Cicek, Muzaffer ;
Metge, Brandon J. ;
Chandramouli, Kondethimmana H. ;
Chambers, Ann F. ;
Casey, Graham ;
Welch, Danny R. ;
Shevde, Lalita A. .
MOLECULAR CANCER, 2007, 6 (1)
[17]   Suppression of murine mammary carcinoma metastasis by the murine ortholog of breast cancer metastasis suppressor 1 (Brms1) [J].
Samant, Rajeev S. ;
Debies, Michael T. ;
Hurst, Douglas R. ;
Moore, Blake P. ;
Shevde, Lalita A. ;
Welch, Danny R. .
CANCER LETTERS, 2006, 235 (02) :260-265
[18]  
Seraj MJ, 2000, CANCER RES, V60, P2764
[19]   Metastasis suppressor pathways - an evolving paradigm [J].
Shevde, LA ;
Welch, DR .
CANCER LETTERS, 2003, 198 (01) :1-20
[20]  
SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201